Name: Latest research reports of Alivus Life Sciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alivus Life Sciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Mid-range Performer

1039.8000 34.20 (3.40%)

NSE Apr 07, 2026 15:31 PM

26.96% Gain from 52W Low

Volume: 98,437

Alivus Life Sciences Ltd.

29 Apr 2023

1039.80

3.40%

Glenmark Life Sciences (BUY): All-round beat

Buy: Alivus Life Sciences Ltd.

Target

BOB Capital Markets Ltd.

Q4 revenue of Rs 6.2bn (+21% YoY) beat our estimate by 14% driven by recovery in CDMO and growth in API

Number of FII/FPI investors increased from 92 to 98 in Dec 2025 qtr.